<?xml version="1.0" encoding="UTF-8"?>


<article dtd-version="1.0" article-type="research-article">
  <front>
      <journal-meta>
         <journal-id xmlns:xlink="http://www.w3.org/1999/xlink" journal-id-type="jstor">intejhealeconman</journal-id>
         <journal-id xmlns:xlink="http://www.w3.org/1999/xlink" journal-id-type="jstor">j50020182</journal-id>
         <journal-title-group xmlns:xlink="http://www.w3.org/1999/xlink">
            <journal-title>International Journal of Health Economics and Management</journal-title>
         </journal-title-group>
      
         <publisher>
            <publisher-name>Springer</publisher-name>
         </publisher>
         <issn xmlns:xlink="http://www.w3.org/1999/xlink" pub-type="ppub">21999023</issn>
         <issn xmlns:xlink="http://www.w3.org/1999/xlink" pub-type="epub">21999031</issn>
         <custom-meta-group xmlns:xlink="http://www.w3.org/1999/xlink"/>
      </journal-meta>
      <article-meta xmlns:xlink="http://www.w3.org/1999/xlink">
         <volume xmlns:mml="http://www.w3.org/1998/Math/MathML"
                 xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table">16</volume>
         <issue xmlns:mml="http://www.w3.org/1998/Math/MathML"
                xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table">4</issue>
         <issue-id>i40228034</issue-id>
         <article-id pub-id-type="doi">10.2307/45271477</article-id>
         <article-categories>
            <subj-group>
               <subject>SHORT PAPER</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title>Can patent duration hinder medical innovation</article-title>
         </title-group>
         <contrib-group>
            <contrib>
               <string-name>
                  <given-names>Patrick</given-names>
                  <surname>Leoni</surname>
               </string-name>
            </contrib>
            <contrib>
               <string-name>
                  <given-names>Alvaro</given-names>
                  <surname>Sandroni</surname>
               </string-name>
            </contrib>
         </contrib-group>
         <pub-date pub-type="ppub">
            <day>1</day>
            <month>12</month>
            <year>2016</year>
         </pub-date>
         <fpage>397</fpage>
         <lpage>406</lpage>
         <self-uri xlink:href="https://www.jstor.org/stable/45271477"/>
      
      
         <abstract>
            <p>We argue that, in the pharmaceutical industry, excessive patent duration can deter investments in innovative treatments in favor of me-too drugs. The point is that too-long durations foster incentives to collude to delay investments in R&amp;D for innovative treatments. We give a set of sufficient conditions for which collusion is a subgame-perfect equilibrium; that is, the threat of punishing any deviator is credible. We then show that reducing current duration always breaks down market discipline, and so does an increase in duration for innovative treatments. Optimal patent duration must then be a trade-off between breaking down market discipline and rewarding innovation.</p>
         </abstract>
         <custom-meta-group>
            <custom-meta>
               <meta-name>lang</meta-name>
               <meta-value>eng</meta-value>
            </custom-meta>
         </custom-meta-group>
      </article-meta>
  </front>
  <back>
    
      <ref-list>
        <title>References</title>
        <ref id="d499e129a1310">
          
            <mixed-citation id="d499e133" publication-type="other">
American Pharmaceutical Research Companies. (2007). Pharmaceutical researchers are testing 92 medicines
and vaccines for HTV and related conditions. Report on Medicines in Development for HIV/AIDS.</mixed-citation>
        </ref>
        <ref id="d499e143a1310">
          
            <mixed-citation id="d499e147" publication-type="other">
Bain, J. (1956). Barriers to new competition. Cambridge, MA: Harvard University Press.</mixed-citation>
        </ref>
        <ref id="d499e154a1310">
          
            <mixed-citation id="d499e158" publication-type="other">
Bernheim, D., &amp; Whinston, M. D. (1990). Multimarket contact and collusive behavior. RAND Journal of
Economics, 21, 1-26.</mixed-citation>
        </ref>
        <ref id="d499e168a1310">
          
            <mixed-citation id="d499e172" publication-type="other">
Borrell, J.-R. (2007). Pricing and patents of HTV/AIDS drugs in developing countries. Applied Economics,
39, 505-518.</mixed-citation>
        </ref>
        <ref id="d499e183a1310">
          
            <mixed-citation id="d499e187" publication-type="other">
Chamberlin, E. (1933). Theory of monopolistic competition. Cambridge, MA: Harvard University Press.</mixed-citation>
        </ref>
        <ref id="d499e194a1310">
          
            <mixed-citation id="d499e198" publication-type="other">
Cornelli, F., &amp; Schankerman, M. (1999). Patent renewals and R&amp;D incentives. The RAND Journal of Eco-
nomics, 30, 197-213.</mixed-citation>
        </ref>
        <ref id="d499e208a1310">
          
            <mixed-citation id="d499e212" publication-type="other">
Denicolo, V. (1999). The optimal life of a patent when the timing of innovation is stochastic. International
Journal of Industrial Organization, 17, 827-846.</mixed-citation>
        </ref>
        <ref id="d499e222a1310">
          
            <mixed-citation id="d499e226" publication-type="other">
Ganuza, J., Llobet, G., &amp; Domnguez, B. (2009). R&amp;D in the pharmaceutical industry: A world of small
innovations. Management Science, 55, 539-551.</mixed-citation>
        </ref>
        <ref id="d499e236a1310">
          
            <mixed-citation id="d499e240" publication-type="other">
Gonzalez, P., Macho-Stadler, I., &amp; Perez-Castrillo, D. (2015). Private versus social incentives for pharmaceu-
tical innovation. IDEAS: Working Papers, Universidad Pablo de Olavide, WP ECON 15.07.</mixed-citation>
        </ref>
        <ref id="d499e250a1310">
          
            <mixed-citation id="d499e254" publication-type="other">
Grabowski, H. (2003). Innovation and R&amp;D incentives for orphan drugs and neglected diseases. Mimeo:
Duke University.</mixed-citation>
        </ref>
        <ref id="d499e265a1310">
          
            <mixed-citation id="d499e269" publication-type="other">
Grabowski, H., &amp; Vernon, J. (1992). Brand loyalty, entry and price competition in pharmaceuticals after the
1984 drug act. Journal of Law and Economics, 35, 331-350.</mixed-citation>
        </ref>
        <ref id="d499e279a1310">
          
            <mixed-citation id="d499e283" publication-type="other">
Grootendorst, P., &amp; Di Matteo, L. (2007). The effect of pharmaceutical patent term Length on research and
development and drug expenditures in Canada. Healthcare Policy, 2, 63-84.</mixed-citation>
        </ref>
        <ref id="d499e293a1310">
          
            <mixed-citation id="d499e297" publication-type="other">
Horowitz, A., &amp; Lai, E. (1996). Patent length and the rate of innovation. International Economic Review, 37,
785-801.</mixed-citation>
        </ref>
        <ref id="d499e307a1310">
          
            <mixed-citation id="d499e311" publication-type="other">
Hudson, J. (2000). Take-up in the pharmaceutical market following patent expiry: A multi-country study.
International Review of Law and Economics, 24, 103-112.</mixed-citation>
        </ref>
        <ref id="d499e321a1310">
          
            <mixed-citation id="d499e325" publication-type="other">
Ito, B., &amp; Yamagata, T. (2007). Who develops innovations in medicine for the poor? Trends in patent applica-
tions related to medicines for HIV/AIDS, tuberculosis, malaria and neglected diseases. The Developing
Economies, 2, 141-171.</mixed-citation>
        </ref>
        <ref id="d499e338a1310">
          
            <mixed-citation id="d499e342" publication-type="other">
Klausner, R. D., et al. (2003). The need for a global HIV vaccine enterprise. Science, 300, 2036-2039.</mixed-citation>
        </ref>
        <ref id="d499e350a1310">
          
            <mixed-citation id="d499e354" publication-type="other">
Kremer, M. (2002). Pharmaceuticals and the developing world. Journal of Economic Perspectives, 16, 67-90.</mixed-citation>
        </ref>
        <ref id="d499e361a1310">
          
            <mixed-citation id="d499e365" publication-type="other">
Kremer, M., &amp; Glennerster, R. (2004). Strong medicine: Creating incentives for pharmaceutical research on
neglected diseases. Princeton, NJ: Princeton University Press.</mixed-citation>
        </ref>
        <ref id="d499e375a1310">
          
            <mixed-citation id="d499e379" publication-type="other">
Leibowitz, A., &amp; Sood, N. (2007). Market power and state costs of HTV/AIDS drugs. International Journal
of Health Care Finance and Economics, 7, 59-71.</mixed-citation>
        </ref>
        <ref id="d499e389a1310">
          
            <mixed-citation id="d499e393" publication-type="other">
Leoni, P. (2010). Economic challenges in the fight against HIV/AIDS. New York: Nova Science Publishers.</mixed-citation>
        </ref>
        <ref id="d499e400a1310">
          
            <mixed-citation id="d499e404" publication-type="other">
Matsushima, H. (2001). Multimarket contact, imperfect monitoring, and implicit collusion. Journal of Eco-
nomic Theory, 98, 158-178.</mixed-citation>
        </ref>
        <ref id="d499e414a1310">
          
            <mixed-citation id="d499e418" publication-type="other">
Offit, P. (2005). Why are pharmaceutical companies gradually abandoning vaccines? Health Affairs, 24, 622-
630.</mixed-citation>
        </ref>
        <ref id="d499e429a1310">
          
            <mixed-citation id="d499e433" publication-type="other">
Sherer, F. (1980). Industrial market structure and economic performance (2nd ed.). Chicago: Rand-McNally.</mixed-citation>
        </ref>
        <ref id="d499e440a1310">
          
            <mixed-citation id="d499e444" publication-type="other">
Urole, J. (1988). The theory of industrial organization. Cambridge, MA: MIT Press.</mixed-citation>
        </ref>
        <ref id="d499e451a1310">
          
            <mixed-citation id="d499e455" publication-type="other">
Trouiller, P. (2012). Drug development for neglected diseases: A deficient market and a public-health policy
failure. The Lancet, 359, 2188-2194.</mixed-citation>
        </ref>
        <ref id="d499e465a1310">
          
            <mixed-citation id="d499e469" publication-type="other">
United States Government Accountability Office. (2006). New drug development: Science, business, regulatory
and intellectual property issues cited as hampening drug development efforts. Report, U.S. Government
Accountability Office, Washington, D.C. http://www.gao.gov/new.items/d0749.</mixed-citation>
        </ref>
      </ref-list>
    
  </back>
</article>


